1
|
Renjini A, Swapna MNS, Sankararaman SI. Graph features based classification of bronchial and pleural rub sound signals: the potential of complex network unwrapped. Phys Eng Sci Med 2024:10.1007/s13246-024-01455-4. [PMID: 38954378 DOI: 10.1007/s13246-024-01455-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Accepted: 06/04/2024] [Indexed: 07/04/2024]
Abstract
The study presents a novel technique for lung auscultation based on graph theory, emphasizing the potential of graph parameters in distinguishing lung sounds and supporting earlier detection of various respiratory pathologies. The frequency spread and the component magnitudes are revealed from the analysis of eighty-five bronchial (BS) and pleural rub (PS) lung sounds employing the power spectral density (PSD) plot and wavelet scalogram. The low-frequency spread, and persistence of the high-intensity frequency components are visible in BS sounds emanating from the uniform cross-sectional area of the trachea. The frictional rub between the pleurae causes a higher frequency spread of low-intensity intermittent frequency components in PS signals. From the complex networks of BS and PS, the extracted graph features are - graph density ([Formula: see text], transitivity ([Formula: see text], degree centrality ([Formula: see text]), betweenness centrality ([Formula: see text], eigenvector centrality ([Formula: see text]), and graph entropy (En). The high values of [Formula: see text] and [Formula: see text] show a strong correlation between distinct segments of the BS signal originating from a consistent cross-sectional tracheal diameter and, hence, the generation of high-intense low-spread frequency components. An intermittent low-intense and a relatively greater frequency spread in PS signal appear as high [Formula: see text], [Formula: see text], [Formula: see text], and [Formula: see text] values. With these complex network parameters as input attributes, the supervised machine learning techniques- discriminant analyses, support vector machines, k-nearest neighbors, and neural network pattern recognition (PRNN)- classify the signals with more than 90% accuracy, with PRNN having 25 neurons in the hidden layer achieving the highest (98.82%).
Collapse
Affiliation(s)
- Ammini Renjini
- Department of Optoelectronics, University of Kerala, Trivandrum, Kerala, 695581, India
| | | | | |
Collapse
|
2
|
He J, Li L, Wang S, Wu S, Xiao W, Li L, Dong L, Ge A, Xie K, Wang J. Abnormal methylation of HOXA11 promoter promotes tumor progression in testicular germ cell tumor. Am J Transl Res 2024; 16:1660-1668. [PMID: 38883380 PMCID: PMC11170575 DOI: 10.62347/hjki7733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2023] [Accepted: 04/19/2024] [Indexed: 06/18/2024]
Abstract
OBJECTIVE To investigate the methylation of HOXA11 gene promoter in testicular germ cell tumor (GCT). METHOD The clinicopathological data of 63 patients with primary testicular GCT who underwent surgery during Apr. 2019 to Mar. 2021, were retrospectively analyzed. Their GCT tissue and paraneoplastic testicular tissue were obtained, and genomic DNA was extracted from both. The methylation of HOXA11 gene promoter region was detected by methylation-specific PCR (MSP). The incidence of HOXA11 methylation in testicular GCT and adjacent tissues was compared, and the connection between methylation level in testicular GCT and clinicopathologic features of patients was statistically analyzed. Testicular GCT cells were treated with methylated transferase inhibitor 5-Aza-dC in vitro, and HOXA11 mRNA expression was detected by real-time PCR. RESULTS The positive rate of HOXA11 promoter methylation in testicular GCT tissues was notably higher than that of paired adjacent tissues (P<0.05). The abnormal methylation of HOXA11 gene promoter was correlated with lymph node metastasis and TNM stage in patients (P<0.05). HOXA11 mRNA expression in testicular GCT cells treated with 5-Aza-dC was increased (P<0.05). CONCLUSION Abnormal methylation of HOXA11 gene promoter in testicular germ cell tumor tissue inhibits transcription and expression of HOXA11 gene. The abnormal methylation of HOXA11 promoter region is tightly associated with lymph node metastasis and TNM staging in testicular germ cell tumors.
Collapse
Affiliation(s)
- Juan He
- Department of Pathology, The Institutes of Shanxi Bethune Hospital Taiyuan 030032, Shanxi, China
| | - Liang Li
- Institutes of Biomedical Sciences, Shanxi University Taiyuan 030006, Shanxi, China
| | - Shengxin Wang
- Institutes of Biomedical Sciences, Shanxi University Taiyuan 030006, Shanxi, China
| | - Shan Wu
- Department of Radiology, The Institutes of Shanxi Bethune Hospital Taiyuan 030032, Shanxi, China
| | - Wenli Xiao
- Department of Ultrasonography, The Institutes of Shanxi Bethune Hospital Taiyuan 030032, Shanxi, China
| | - Li Li
- Department of Pathology, The Institutes of Shanxi Bethune Hospital Taiyuan 030032, Shanxi, China
| | - Li Dong
- Institutes of Biomedical Sciences, Shanxi University Taiyuan 030006, Shanxi, China
| | - An Ge
- Institutes of Biomedical Sciences, Shanxi University Taiyuan 030006, Shanxi, China
| | - Kaikai Xie
- Institutes of Biomedical Sciences, Shanxi University Taiyuan 030006, Shanxi, China
| | - Jiaomin Wang
- Department of Foreign Language, Shanxi Medical University Taiyuan 030006, Shanxi, China
| |
Collapse
|
3
|
Baltodano-Calle MJ, Onton-Díaz M, Gonzales GF. Androgens, brain and androgen deprivation therapy in paraphilic disorders: A narrative review. Andrologia 2022; 54:e14561. [PMID: 35995581 DOI: 10.1111/and.14561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 07/26/2022] [Accepted: 08/04/2022] [Indexed: 11/27/2022] Open
Abstract
Sexual delinquency is a global problem where those with paraphilic disorders, such as paedophiles, are more likely to commit and reoffend. Androgen deprivation therapy (ADT) has been suggested as a solution. The objective of this narrative review is to present current information on its risks, benefits and limitations as a treatment for paraphilias. The importance of testosterone in sexual function, the effect of its deficiency by age or by pharmacological treatment (anti-androgens, GnRH agonists and GnRH antagonists) and the effect of testosterone replacement therapy will be reviewed. The relationship between androgens, brain, sexual behaviour and pathophysiology of paraphilic disorders will also be explored. ADT reduces sexual urges, but has adverse effects and, because its reversible nature, it does not ensure less recidivism. Likewise, the research quality of ADT drugs is limited and not enough to support their use. Child sex offenders, and not paraphilic subjects who have not committed assaults, show signs of elevated prenatal exposure to androgens and a higher methylation state of the androgen receptor gene. Sexual behaviour is regulated by subcortical (hypothalamus, brainstem and spinal cord) and cortical structures of the brain, in addition to brain circuits (dopaminergic, serotonergic). Those with paraphilic disorders show abnormalities at these levels that could relate to the risk of sexual offences. In conclusion, androgens represent a significant part of the pathophysiology of paraphilias and therefore, ADT seems promising. Nonetheless, more studies are needed to make definite conclusions about the efficacy of long-term ADT in paraphilic patients.
Collapse
Affiliation(s)
| | - Melisa Onton-Díaz
- Faculty of Medicine, Cayetano Heredia Peruvian University., Lima, Peru
| | - Gustavo F Gonzales
- Laboratorio de Endocrinología y Reproducción, Laboratorios de Investigación y Desarrollo (LID), Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru.,Departamento de Ciencias Biológicas y Fisiológicas, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru.,Instituto de Investigaciones de la Altura, Universidad Peruana Cayetano Heredia, Lima, Peru
| |
Collapse
|
4
|
Ng DQ, Chan D, Agrawal P, Zhao W, Xu X, Acharya M, Chan A. EVIDENCE OF BRAIN-DERIVED NEUROTROPHIC FACTOR IN AMELIORATING CANCER-RELATED COGNITIVE IMPAIRMENT: A SYSTEMATIC REVIEW OF HUMAN STUDIES. Crit Rev Oncol Hematol 2022; 176:103748. [PMID: 35718064 DOI: 10.1016/j.critrevonc.2022.103748] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Revised: 06/02/2022] [Accepted: 06/13/2022] [Indexed: 12/27/2022] Open
Abstract
Brain-derived neurotrophic factor (BDNF) plays an essential role in neurogenesis and neuroplasticity and may be a key protein in cancer-related cognitive impairment (CRCI). This systematic review assessed the relationship between BDNF biomarkers and neurocognitive outcomes in cancer patients and survivors. A search in PubMed, Scopus, and PsycINFO yielded 638 articles, of which 26 were eligible. Fourteen (54%)studied BDNF protein levels while 15 (58%) analyzed BDNF rs6265 polymorphism. Of the nine observational studies reporting BDNF plasma/serum levels, five (56%) exhibited a positive association between BDNF and cognitive function. One study reported intra-tumoral BDNF levels that were negatively associated with memory. For rs6265, three (20%) of 15 studies reported an association with cognitive function with inconsistent directions. Among seven neuroimaging studies, three (43%) demonstrated an effect of BDNF on brain function and structure. These results suggest that BDNF is a potential monitoring biomarker and druggable target for CRCI.
Collapse
Affiliation(s)
- Ding Quan Ng
- Department of Clinical Pharmacy Practice, University of California, Irvine, Irvine, California, United States of America; Department of Pharmaceutical Sciences, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, Irvine, California, United States of America
| | - Daniella Chan
- Department of Pharmaceutical Sciences, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, Irvine, California, United States of America
| | - Parisa Agrawal
- Department of Pharmaceutical Sciences, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, Irvine, California, United States of America
| | - Weian Zhao
- Department of Pharmaceutical Sciences, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, Irvine, California, United States of America; Department of Biological Chemistry, University of California, Irvine, Irvine, California, USA; Department of Biomedical Engineering, The Henry Samueli School of Engineering, University of California, Irvine, Irvine, California, USA; Institute for Immunology, University of California, Irvine, Irvine, California, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, California, USA; Edwards Life Sciences Center for Advanced Cardiovascular Technology, University of California, Irvine, Irvine, California, USA; Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, California, USA
| | - Xiangmin Xu
- Department of Anatomy and Neurobiology, University of California, Irvine, Irvine, California, USA; The Center for Neural Circuit Mapping, University of California Irvine, Irvine, California, USA
| | - Munjal Acharya
- Department of Anatomy and Neurobiology, University of California, Irvine, Irvine, California, USA; Department of Radiation Oncology, School of Medicine, University of California, Irvine, Irvine, California, USA
| | - Alexandre Chan
- Department of Clinical Pharmacy Practice, University of California, Irvine, Irvine, California, United States of America; Department of Pharmaceutical Sciences, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, Irvine, California, United States of America; Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, California, USA.
| |
Collapse
|